Vendor, Allschwil, CHE, part of Basilea Pharmaceutica AG
Basilea Pharmaceutica International Ltd., Allschwil
UEI UA43HWRNXFS3, CAGE SSU10
2 awards and $54,870,405 obligated between February 24, 2026 and August 4, 2026, 100% under full and open competition, against 1.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $54,870,405 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $54,870,405 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50124C00033Definitive Contract, April 24, 2026, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This No Cost Modification Is to Extend the Period of Performance for Clin0001 Through September 30, 2031, Updates Article V: NAICS 541714, PSC AN42 | $30,000,000 |
| 75A50123C00050Definitive Contract, February 24, 2026, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This Modification Is to Exercise Clin0005/Option 4, Update Articles G.3 Key Personnel, G.4.G Contract Financial Report, G.8 PNAICS 541714, PSC AN13 | $24,870,405 |
- Places of performance
- Pennsylvania
- Product and service codes
- AN42 Health R&D Services; Health Care - Other; Applied ResearchAN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 5 across 2 awards